• SinoMab BioScience completed the sale of its Suzhou property and facility on November 4, 2026, relinquishing all interests in the assets.
• All conditions required under the sale and purchase agreement were fulfilled.
• The disposal supports the group's shift toward an asset-light model, with greater focus on early-stage research and clinical development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SinoMab BioScience Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261104-12400764), on November 04, 2026, and is solely responsible for the information contained therein.